Susan Stimson

Susan Stimson joined Avelas Biosciences’ board of directors in 2019. With over 20 years of experience in healthcare, Susan is recognized as a respected leader in the development and commercialization of new medical technologies. She currently serves as the President at Zenflow. Prior, Ms. Stimson is an Executive in Residence on KCK Group’s Medical Technology team, where she applies her expertise to their portfolio of commercial-stage MedTech companies and evaluates new investment opportunities. She previously served as Chief Strategy Officer of Intersect ENT, a publicly-traded medical device company. As part of the founding team of Intersect ENT, Susan played an instrumental role in the company’s evolution from the R&D stage to high growth commercial business by building and leading a variety of its commercial and strategic functions including Marketing, Market Access, International Sales, Business Development and Customer Service and also led the company’s transformation from the medical device to pharmaceutical business as General Manager. Prior to that, Ms. Stimson served as an executive of start-up company Mitralign, designing and executing the company’s marketing, clinical, and regulatory strategies. Her experience stems from many years at Guidant Corporation responsible for top priority products from the aspects of R&D, marketing, and sales. Ms. Stimson holds a B.S. in Biomedical Engineering from Marquette University, Milwaukee, Wisconsin.